Clamp, A. R., James, E. C., McNeish, I. A., Dean, A., Kim, J., O'Donnell, D. M., Gallardo-Rincon, D., Blagden, S., Brenton, J., Perren, T. J., Sundar, S., Lord, R., Dark, G., Hall, M., Banerjee, S., Glasspool, R. M., Hanna, C. L., Williams, S., Scatchard, K. M., Nam, H., Essapen, S., Parkinson, C., McAvan, L., Swart, A. M., Popoola, B., Schiavone, F., Badrock, J., Fananapazir, F., Cook, A. D., Parmar, M., Kaplan, R., & Ledermann, J. A. (2022). weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet oncology, 23(7), 919–930. http://access.bl.uk/ark:/81055/vdc_100158009679.0x00003a